Day: December 9, 2024

Dijon, France, December 09, 2024, 07:30 CET – Crossject (ISIN: FR0011716265; Euronext: ALCJ), a specialty pharma company developing the award-winning needle-free ZENEO® autoinjector to deliver life-saving medicines in emergency situations, and the U.S. Department of Defense (DOD), have relaunched their cooperative research on needle-free autoinjectors, signing an extension of their Cooperative Research and Development Agreement (CRADA) from October 2019. As part of the agreement, the DOD will evaluate an upgraded version of the company’s proprietary needle-free autoinjector ZENEO®. “We are glad to extend our agreement with the DOD’s Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEO-CBRND). Our innovative autoinjector Zeneo® can offer military personnel and untrained first responders an immediate,...

Reference is made to the stock exchange notice on 1 October 2024 by Havila Shipping ASA (“Havila Shipping”) which provided information on lenders’ decisions to either settle or extend their outstanding loans under the restructuring agreement. NOK 1,022 million of debt matures on 30 December 2024, whereof NOK 500 million shall be settled in cash and NOK 522 million shall be converted to shares. In order to refinance the 30 December 2024 maturities, Havila Finans AS a company wholly owned by Havila Holding AS (50.96% owner of Havila Shipping), has mandated Arctic Securities AS to carry out a series of fixed income meetings. A new 2-year NOK 525 million senior secured callable bond issue will follow. The net proceeds from the bond issue will be on-lent to subsidiaries of Havila Shipping and used to repay in full the debt that shall...

To Nasdaq Copenhagen A/S 9 December 2024    New Final Bond Terms for Nykredit Realkredit A/S’s Base Prospectus dated 8 May 2024 In connection with the opening of new ISINs under Nykredit Realkredit A/S’s Base Prospectus dated 8 May 2024, Nykredit issues new Final Bond Terms. The Final Bond Terms for series 01E are stated below. Nykredit Realkredit A/S’s Base Prospectus dated 8 May 2024 and the relevant Final Bond Terms are available for download in Danish and English. In the event of discrepancies between the original Danish text and the English translation, the Danish text shall prevail. The documents can be found on Nykredit’s website at nykredit.com/ir.ISINSeries Currency Coupon Loan repayment profile MaturityDK0009549693 01E DKK 2% Annuity 01.10.2036DK0009549776 01E DKK 3.5% Annuity with up to 10...

Madrid, December 9 – Spanish listed company Lleida.net (BME: LLN) (EPA: ALLLN) (OTCQX: LLEIF) saw a 38.6% increase in the number of clients with monthly billings of more than EUR5,000 in the last year. And, with respect to customers with billings of less than €500 per month, the company saw year-over-year growth of 13.6 percent. Lleida.net, which is listed in Madrid, Paris, New York, Stuttgart and Frankfurt, recorded cumulative sales of 13.95 million euros in the last three quarters of 2024, 12 percent more than last year. As of September 30, 2024, the company’s cumulative EBITDA is €2.21 million, 1322% above the cumulative as of September 30, 2023. The company recently announced the signing of two new contracts with the Colombian government worth 665,000 euros. Lleida.net, founded in 1995, has received more than 300 patents...

SHENZHEN, CHINA, Dec. 08, 2024 (GLOBE NEWSWIRE) — On 6 December, China Medical System Holdings Limited (“CMS” or the “Group”) is pleased to announce that the first prescriptions for the innovative drug Lumeblue® (Methylthioninium Chloride Enteric-coated Sustained-release Tablets) (the “Product”) have been issued in China, which marks that the first oral methylthioninium chloride enteric-coated sustained-release tablets in China has officially entered clinical application. The Product is indicated for enhancing visualization of colorectal lesions in adult patients undergoing screening or surveillance colonoscopies. Lumeblue® is an oral diagnostic drug that uses patented multi-matrix (MMXTM) technology to deliver active substances directly to the colon and release them locally in a controlled manner. As an enhancer dye, the Product...

‘Exterior of the Lead Real Estate Co., Ltd. New Apartment Hotel, ENT TERRACE GINZA PREMIUM‘Exterior of the Lead Real Estate Co., Ltd. New Apartment Hotel, ENT TERRACE GINZA PREMIUMInterior of ENT TERRACE GINZA PREMIUM apartment hotelInterior of ENT TERRACE GINZA PREMIUM apartment hotelInterior of ENT TERRACE GINZA PREMIUM apartment hotelInterior of ENT TERRACE GINZA PREMIUM apartment hotelInterior of ENT TERRACE GINZA PREMIUM apartment hotelInterior of ENT TERRACE GINZA PREMIUM apartment hotelTOKYO, Dec. 08, 2024 (GLOBE NEWSWIRE) — Lead Real Estate Co., Ltd. (Nasdaq: LRE) (“LRE” or “the Company”), a Japanese real estate developer of luxury residential properties including single-family homes and condominiums across Tokyo, Kanagawa prefecture and Sapporo, today announced the...

ROAD TOWN, British Virgin Islands, Dec. 08, 2024 (GLOBE NEWSWIRE) — Aura Minerals Inc. (TSX: ORA) (B3: AURA33) (OTCQX: ORAAF) (“Aura” or the “Company”) is pleased to announce encouraging exploration and drilling results from several high-potential projects in Brazil. These include the Pé Quente Project, located 34 km from the Matupá Project’s X1 Deposit; near-mine expansion at the Paiol Deposit, part of the Almas Mine; and Aura Carajás, all of which are located in Brazil. These results highlight the Company’s ongoing success in advancing its exploration portfolio and reaffirm Aura’s commitment to expanding its resource and reserve base, positioning the Company for sustained growth. HighlightsPé Quente ProjectThe Pé Quente gold deposit is emerging as one of the most significant disseminated gold systems in granitic environments...

Demonstrated durable hematologic response across all patient subgroups, regardless of baseline transfusion status and concomitant JAK inhibitor therapy Phase 2 study in MF anemia has been initiated, enrolling a broad range of patient typesWATERTOWN, Mass., Dec. 08, 2024 (GLOBE NEWSWIRE) — Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases, today presented positive updated results from a Phase 1b trial of DISC-0974 in patients with myelofibrosis (MF) and anemia. The data, presented in an oral session at the 2024 American Society of Hematology (ASH) annual meeting in San Diego, CA, demonstrated that treatment with DISC-0974 results in substantial reductions in hepcidin...